AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) posted its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07, FiscalAI reports. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The firm had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

Here are the key takeaways from AngioDynamics’ conference call:

• Revenue grew 6.9% to $80.9 million, driven by 13.2% growth in Med Tech, which now represents 49% of sales and is expected to become the majority of revenue this fiscal year. Med Device revenue grew a steadier 1.4% and continues to provide cash flow for Med Tech investments.
• Key growth platforms continued to perform well: Auryon delivered its 21st consecutive quarter of double-digit growth, AlphaVac revenue rose 37.4%, and NanoKnife revenue increased 29% on record prostate procedure volumes. Management cited further catalysts from AlphaReturn trial enrollment, broader NanoKnife reimbursement, and the RELIEF BPH study.
• Profitability improved, with adjusted EBITDA rising to $5.0 million from $2.2 million and adjusted loss per share narrowing to $0.04 from $0.10. Gross margin reached 59.4%, or 57.8% excluding tariff refunds, supported by pricing and favorable product mix.
• Management maintained fiscal 2027 guidance for revenue of $336 million–$341 million, Med Tech growth of 12%–15%, gross margin of 54%–55%, adjusted EBITDA of $13 million–$16 million, and an adjusted loss per share of $0.29–$0.24. The company expects positive operating cash flow for the full year, although it ended the quarter with $34 million in cash after using $15.3 million in operating cash.
• CEO Jim Clemmer will retire, with Eric Honroth appointed as president and CEO effective November 2; management characterized the transition as planned and expressed confidence in Honroth’s medical-device leadership experience. AngioVac revenue declined 5.9% year over year due to a difficult comparison, though sequential growth and underlying demand were described as improving.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $11.23 on Friday. The company has a market capitalization of $472.22 million, a P/E ratio of -12.91 and a beta of 0.30. The business has a fifty day simple moving average of $15.39 and a two-hundred day simple moving average of $13.11. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.00% of the company’s stock.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of approximately $80.9 million, up 6.9% year over year and slightly above analyst expectations. The company’s reported loss of $0.04 per share was also better than the consensus estimate of a $0.11 loss. AngioDynamics Fiscal Q1 Earnings Snapshot
• Positive Sentiment: Gross margin expanded to 59.4%, an improvement of 410 basis points from the prior-year quarter. Med Tech sales rose 13.2% to $39.9 million, led by Auryon growth of 14.7% and NanoKnife growth of 29.0%. AngioDynamics Fiscal Q1 Financial Results
• Positive Sentiment: The company received FDA IDE approval for a feasibility study evaluating NanoKnife irreversible electroporation for benign prostatic hyperplasia, potentially expanding the technology’s addressable market. AngioDynamics Reports First-Quarter Sales
• Neutral Sentiment: Management reaffirmed fiscal 2027 revenue guidance of $336 million to $341 million and adjusted EPS guidance of a $0.24 to $0.29 loss. The outlook is broadly consistent with analysts’ expectations, offering limited upside surprise. AngioDynamics Fiscal 2027 Outlook
• Negative Sentiment: AngioDynamics remains unprofitable, with a GAAP net loss of roughly $7.1 million and continued negative margins. Operating cash flow was also negative at $15.3 million, while cash stood at $34.0 million at quarter-end.
• Negative Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. Although Honroth brings industry experience, the leadership change introduces execution uncertainty and likely contributed to the market’s negative reaction. AngioDynamics Announces New CEO

Analyst Ratings Changes

A number of brokerages recently commented on ANGO. Zacks Research raised AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright upped their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Finally, Canaccord Genuity Group lifted their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AngioDynamics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.